A modern view of the immunopathogenesis of chronic hepatitis B


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Chronic HBV infection is a dynamic process that reflects the interaction between HBV replication and the host immune response. The data available in the literature show that in chronic hepatitis B, it is precisely the quantitative composition and functions of innate immune cells which have a pronounced effect on the virus. A deep insight into the immunopathogenetic mechanisms caused by individual antigenic HBV components that cause both chronic hepatitis B and its adverse outcomes will serve as the basis for using prognostically significant methods for immunodiagnosis, as well as for effective treatment and prevention of the disease.

Full Text

Restricted Access

About the authors

Khadizhat G. Omarova

Central Research Institute of Epidemiology Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: omarova71@inbox.ru
Cand. Med. Sci., Researcher, Clinical Department of Infectious Diseases Moscow, Russia

Vera V. Makashova

Central Research Institute of Epidemiology Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: veramakashova@yandex.ru
Prof., MD, Leading Researcher Moscow, Russia

Zhanna B. Ponezheva

Central Research Institute of Epidemiology Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: doktorim@mail.ru
MD, Head, Clinical Department of Infectious Diseases Moscow, Russia

Olga N. Khokhlova

Central Research Institute of Epidemiology Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: x.olia79@mail.ru
Cand. Med. Sci., Researcher, Clinical Department of Infectious Diseases Moscow, Russia

References

  1. World Health Organization. Global hepatitis report, April 2017; 83. https://www.who.int/hepatitis/publications/global-hepatitis-report 2017/en/
  2. World Health Organization. Hepatitis В Fact Sheet. http://www. who.int/mediacentre/factsheets/fs204/en/
  3. EASL 2017. Clinical Practice Guidelines on the management of hepatitis В virus infection. J. Hepatol. 2017; 67: 370-98. https://doi.org/10.1016/j.jhep.2017.03.021
  4. Жданов К.В., Лобзин Ю.В., Гусев Д.А., Козлов К.В. Вирусные гепатиты. СПб: Фолиант, 2011. 304 с.
  5. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis В virus infection. J. Hepatol. 2012; 57: 167-85.
  6. Schweitzer A., Horn J., Mikolajczyk R.T., Krause G., Ott J.J. Estimations of worldwide prevalence of chronic hepatitis В virus infection: A systematic review of data published between 1965 and 2013. Lancet 2015; 386: 1546-55.
  7. Абдурахманов Д.Т. Хронический гепатит В и D. М.: ГЭОТАР-Медиа, 2010. 288 с.
  8. Baumert T.F., Thimme R., von Weizsäcker F. Pathogenesis of hepatitis В virus infection. World J. Gastroenterol. 2007; 13: 82-90. https://doi.org/ 10.3748/wjg.v13.i1.82
  9. Balmasova I.P., Yushchuk N.D., Mynbayev O.A., Alla N.R., Malova E.S., Shi Z., Gao K.I. [Immunopathogenesis of chronic hepatitis В]. World J. Gastroenterol. 2014; 20 (39): 14156-71. doi: 10.3748/wjg.v20.i39.14156
  10. Suk-Fong Lok A. Hepatitis B Treatment: What We Know Now and What Remains to Be Researched. Hepatol. Commun. 2018; 3(1): 8-19. doi: 10.1002/hep4.1281
  11. Seeger C., Mason W.S. Molecular biology of hepatitis B virus infection J. Virol. 2015; 479-480: 672-86. https://doi.org/10.1016/j.virol.2015.02.031
  12. Lee J., Shin M.K., Lee H.J., Yoon G., Ryu W.S. Three novel cis-acting elements required for efficient plus-strand DNA synthesis of the hepatitis B virus genome. J. Virol. 2004; 78: 7455- 64. doi: 10.1128/JVI.78.14.7455-7464.2004
  13. Bertoletti A., Kennedy P.T. The immune tolerant phase of chronic HBV infection: new perspectives on an old concept. Cell Mol. Immunol. 2015; 12(3): 258-63. doi: 10.1038/cmi.2014.79
  14. Said Z.N. An overview of occult hepatitis B virus infection. World. J. Gastroenterol. 2011; 17(15): 1927-38. doi: 10.3748/wjg.v17. i15.1927.
  15. Wong D.K., Huang F.Y., Lai C.L., Poon R.T, Seto W.K., Fung J. et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology 2011; 54: 829-36. doi: 10.1002/hep.24551
  16. Roseman A.M., Borschukova O., Berriman J.A., Wynne S.A., Pumpens P., Crowther R.A. Structures of hepatitis B virus cores presenting a model epitope and their complexes with antibodies. J. Mol. Biol. 2012; 423(1): 63-78. doi: 10.1016/j.jmb.2012.06.032.
  17. Block T.M., Mehta A.S., Blumberg B.S., Dwek R.A. Does rapid oligomerization of hepatitis B envelope proteins play a role in resistance to proteasome degradation and enhance chronicity? DNA Cell Biol. 2006; 25 (3):165-70. doi: 10,1089/dna.2006.25.165
  18. Li L., Liu M., Cheng L.W., Gao X.Y., Fu J.J., Kong G. et al. HBcAg-specific IL-21-producing CD4+ T cells are associated with relative viral control in patients with chronic hepatitis B. Scand. J. Immunol. 2013; 78(5): 439-46. doi: 10.1111/sji.12099
  19. Buchmann P., Dembek C., Kuklick L., Jäger C., Tedjokusumo R., von Freyend M.J. et al. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice. Vaccine 2013; 31(8):1197-203. doi: 10.1016/ j.vaccine.2012.12.074
  20. You J., Sriplung H., Geater A., Chongsuvivatwong V., Zhuang L., Chen H.Y. et al. Effect of viral load on T-lymphocyte failure in patients with chronic hepatitis B. World J Gastroenterol. 2008; 14(7): 1112-9. doi: 10.3748/wjg.14.1112
  21. Block T.M., Guo H., Guo J.T. Molecular virology of hepatitis B virus for clinicians. Clin. Liver Dis. 2007; 11(4): 685-706. doi: 10.1016/j.cld.2007.08.002
  22. Shi Y.H., Shi C.H. Molecular characteristics and stages of chronic hepatitis B virus infection. World J. Gastroenterol. 2009; 15(25): 3099-105. doi: 10.3748/wjg.15.3099
  23. Li N., Li Q., Qian Z., Zhang Y., Chen M., Shi G. Impaired TLR3/ IFN-beta signaling in monocyte-derived dendritic cells from patients with acute-on-chronic hepatitis B liver failure: relevance to the severity of liver damage. Biochem. Biophys. Res. Commun. 2009; 390(3):.630-5. doi: 10.1016/j.bbrc.2009.10.018
  24. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008; 214(2): 199-210. doi: 10,1002/path.2277
  25. Shi F., Zhang J.Y, Zeng Z., Tien P., Wang F.S. Skewed ratios between CD3(+) T cells and monocytes are associated with poor prognosis in patients with HBV-related acute-on-chronic liver failure. Biochem. Biophys. Res. Commun. 2010; 402(1): 30-6. doi: 10.1016/j.bbrc.2010.09.096
  26. Feitelson M.A., Reis H.M.G.P.V., Liu J., Lian Z., Pan J. Hepatitis B virus X antigen (HBxAg) and cell cycle control in chronic infection and hepatocarcinogenezis. Frontiers in Bioscience 2005; 10: 155872. doi: 10,2741/1640
  27. Zhang Z., Zhang J.Y., Wang L.F., Wang F.S. Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection. J. Gastroenterol. Hepatol. 2012; 27(2): 223-30. doi: 10.1111/j.1440-1746. 2011.06940.x
  28. Kim J.Y., Song E.H., Lee H.J., Oh Y.K., Choi K.H., Yu D.Y et al. HBx-induced hepatic steatosis and apoptosis are regulated by TNFR1- and NF-kappaB-dependent pathways. J. Mol. Biol. 2010; 397(4): 917-31. doi: 10.1016/j.jmb.2010.02.016
  29. Dunn C., Brunetto M., Reynolds G., Christophides T., Kennedy P.T., Lampertico P. et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J. Exp. Med. 2007; 204(3): 667-80. doi: 10.1084/ jem.20061287
  30. Ratnam D., Visvanathan K. New concepts in the immunopathogenesis of chronic hepatitis B: the importance of the innate immune response. Hepatol. Int. 2008; 2(Suppl.1): 12-8. doi: 10.1007/s12072-008-9067-0
  31. Chen J., Wu M., Zhang X., Zhang W., Zhang Z., Chen L. et al. Hepatitis B virus polymerase impairs interferon-a-induced STAT activation through inhibition of importin-a5 and protein kinase C-б. Hepatology 2013; 57(2): 470-82. doi: 10.1002/hep.26064
  32. Ito T., Kanzler H., Duramad O., Cao W., Liu Y.J. Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells. Blood 2006; 107(6): 2423-31. DOI: 10,1182/кровь-2005-07-2709
  33. Ma Y.J., He M., Han J.A., Yang L., Ji X.Y. A clinical study of HBsAg-activated dendritic cells and cytokine-induced killer cells during the treatment for chronic hepatitis B. Scand. J. Immunol. 2013; 78(4): 387-93. doi: 10.1111/sji.12097
  34. Хохлова О.Н., Серебровская Л.В., Ходжибеков Р.Р., Гезахегне Д.Б., Кожевникова Г.М., Покровский В.В., Рейзис А.Р. Роль плазмоцитоидных дендритных клеток как новых иммуноцитов в патогенезе ХГС, ХГВ И ВИЧ-инфекции. Инфекционные болезни 2016; 14(4): 31-6.
  35. Woltman A.M., Ter Borg M.J., Binda R.S., Sprengers D., von Blomberg B.M., Scheper R.J. et al. Alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebocontrolled Phase I/II trial. Antivir. Ther. 2009; 14(6): 809-18. doi: 10,3851/IMP1295
  36. Sun H.H., Zhou D.F., Zhou J.Y. The role of DCs in the immunopathogenesis of chronic HBV infection and the methods of inducing DCs maturation. J. Med. Virol. 2016; 88: 13-20. doi: 10.1002/jmv.24306
  37. Duan X.Z., Wang M., Li H.W., Zhuang H., Xu D., Wang F.S. Decreased frequency and function of circulating plasmocytoid dendritic cells (pDC) in hepatitis B virus infected humans. J. Clin. Immunol. 2004; 24(6): 637-46. doi: 10.1007/s10875- 004-6249-y
  38. Opden Brouw M.L., Binda R.S., van Roosmalen M.H., Protzer U., Janssen H.L., van der Molen R.G., Woltman A.M. Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology 2009; 126(2): 280-9. doi: 10.1111/j.1365-2567.2008.02896.x
  39. Сепиашвили Р.И., Балмасова И.П., Кабанова Е.В., Малова Е.С., Славянская Т.А. Вирус гепатита В: биология, иммунопатогенез, система NK/NKT в вирусной персистенции. Журн. микробиол., эпидемиол., иммунол. 2006; (6): 76-83. PMID: 17163145
  40. Lang K.S., Georgiev P., Recher M., Navarini A.A., Bergthaler A., Heikenwalder M. et al. Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. J. Clin. Invest. 2006; 116(9): 2456-63. DOI: 10,1172/JCI28349
  41. Moretta A., Marcenaro E., Parolini S., Ferlazzo G., Moretta L. NK cells at the interface between innate and adaptive immunity. Cell Death. Differ. 2008; 15(2): 226-33. DOI: 10,1038/sj.cdd.4402170
  42. Stoop J.N., Woltman A.M., Biesta P.J., Küsters J.G., Kuipers E.J., Janssen H.L., van der Molen R.G. Tumor necrosis factor alpha inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response. Hepatology 2007; 46(3): 699705. doi: 10.1002/hep.21761
  43. Jinushi M., Takehara T., Tatsumi T., Yamaguchi S., Sakamori R., Hiramatsu N. et al. Natural killer cell and hepatic cell interaction via NKG2A leads to dendritic cell-mediated induction of CD4+CD25+ T cells with PD-1-dependent regulatory activities. Immunology 2007; 120(1): 73-82. DOI: 10,1111/j.1365-2567.2006.02479.x
  44. Weng P.J., Ying H., Hong L.Z., Zhou W.H., Hu Y.R., Xu C.H. An analysis of CD3+CD56+ lymphocytes and their subsets in the peripheral blood of patients with chronic hepatitis B. Zhonghua Ganzangbing Zazhi 2008; 16(9): 654-6.
  45. Rauch A., Laird R., McKinnon E., Telenti A., Furrer H., Weber R. et al. Influence of inhibitory killer immunoglobulinlike receptors and their HLA-C ligands on resolving hepatitis C virus infection. Tissue Antigens 2007; 69 (Suppl 1): 237-40. DOI: 10,1111/j.1399-0039.2006.773_4.x
  46. Peng G., Li S., Wu W., Sun Z., Chen Y., Chen Z. Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection. Immunology 2008; 123(1): 57-65. doi: 10.1111/j.1365-2567.2007.02691.x
  47. Zhang L., Zhao Y. The regulation ofFoxp3 expression in regulatory CD4(+) CD25(+) T cells: multiple pathways on the road. J. Cell Physiol. 2007; 211(3): 590-97. doi: 10.1002/jcp.21001
  48. Marson A., Kretschmer K., Frampton G.M., Jacobsen E.S., Polansky J.K., MacIsaac K.D. et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 2007; 445(7130): 931-5. doi: 10.1038/nature05478
  49. Manigold T., Racanelli V. T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections: facts and controversies. Lancet Infect. Dis. 2007; 7(12): 804-13. doi: 10.1016/S1473-3099 (07)70289-X
  50. Guo J.C., Bao J.F., Chen Q.W., Li X.O., Shi J.P., Lou G.Q. et al. Level of serum and liver tissue TGF-beta1 in patients with liver fibrosis due to chronic hepatitis B. Zhonghua Shiyan He Linchuangbingduxue Zazhi 2008; 22(5): 354-7.
  51. Fallarino F., Grohmann U., You S., McGrath B.C., Cavener D.R., Vacca C. et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 2006; 176(11): 6752-61. doi: 10.4049/jimmunol.176.11.6752
  52. Aalaei-Andabili S.H., Alavian S.M. Regulatory T cells are the most important determinant factor of hepatitis B infection prognosis: a systematic review and meta-analysis. Vaccine 2012; 30(38): 5595602. doi: 10.1016/j.vaccine.2012.06.063
  53. Feng I.C., Koay L.B., Sheu M.J., Kuo H.T., Sun C.S., Lee C. et al. HBcAg-specific CD4+CD25+ regulatory T cells modulate immune tolerance and acute exacerbation on the natural history of chronic hepatitis B virus infection. J. Biomed. Sci. 14(this issue), doi: 10.1007/s11373-006-9129-z
  54. Shimizu Y. T-cell immunopathogenesis and immunotherapeutic strategies for chronic hepatitis B virus infection. World. J. Gastroenterol. 2012; 18(20): 2443-51. doi: 10.3748/wjg.v18. i20.2443
  55. Chen J., Wang X.M., Wu X.J., Wang Y., Zhao H., Shen B., Wang G.Q. Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B. Inflamm. Res. 2011; 60(1): 47-53. doi: 10.1007/s00011-010-0233-1
  56. Nan X.P., Zhang Y., Yu H.T., Li Y., Sun R.L., Wang J.P., Bai X.F. Circulating CD4+CD25 high regulatory T cells and expression of PD-1 and BTLA on CD4+ T cells in patients with chronic hepatitis B virus infection. Viral Immunol. 2010; 23(1): 63-70. doi: 10.1089/vim.2009.0061
  57. Zhang G.L., Xie D.Y., Lin B.L., Xie C., Ye Y.N., Peng L. et al. Imbalance of interleukin-17-producing CD4 T cells/regulatory T cells axis occurs in remission stage of patients with hepatitis B virus-related acute-on-chronic liver failure. J. Gastroenterol. Hepatol. 2013; 28(3): 513-21. doi: 10.1111/jgh.12082
  58. Kitani A., Xu L. Regulatory T cells and the induction of IL-17. Mucosal Immunol. 2008; 1(Suppl 1): S43-S46. doi: 10.1038/ mi.2008.51
  59. Zhang G.L., Xie D.Y., Ye Y.N., Lin C.S., Zhang X.H., Zheng Y.B. et al. High level of IL-27 positively correlated with Th17 cells may indicate liver injury in patients infected with HBV. Liver Int. 2014; 34(2): 266-73. doi: 10.1111/liv.12268
  60. Zerbini A., Pilli M., Boni C., Fisicaro P., Penna A., Di Vincenzo P. et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 2008; 134(5): 1470-81. doi: 10.1053/j. gastro.2008.02.017

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies